Edition:
United Kingdom

People: Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

34.30USD
23 Aug 2019
Change (% chg)

$-0.26 (-0.75%)
Prev Close
$34.56
Open
$34.56
Day's High
$34.81
Day's Low
$34.24
Volume
236,291
Avg. Vol
303,458
52-wk High
$41.52
52-wk Low
$32.36

Bjorklund, Hakan 

Dr. Hakan Bjorklund has served as Independent Chairman of the Supervisory Board of Qiagen N.V. since June 2018. He served as Independent Member of the Supervisory Board of the Company between March 2017 and June 2018. He is Member of the Compensation Committee, and Chairman of the Selection and Appointment Committee of the Company. Dr. Bjorklund brings an international background in the life science industry to QIAGEN, in particular through his current role as Operating Executive at Avista Capital Partners, as well as through previous roles as CEO of the global pharmaceutical company Nycomed, Regional Director at Astra (now AstraZeneca) and President of Astra Draco. Under Mr. Bjorklund’s leadership, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company. In addition to QIAGEN, he currently serves as Chairman of the Board of Directors at Acino International AG, Swedish Orphan Biovitrum AB (Sobi) and Trimb Healthcare AB. Dr. Bjorklund earlier served as Chairman of the Board of Directors of Lundbeck A/S, and was also a Member of the Board of Directors of several international life science companies, including Alere, Atos, Coloplast and Danisco. He has a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.

Basic Compensation

Total Annual Compensation, USD 123,750
Restricted Stock Award, USD 9,866
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 133,616

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --